![\"\"](\"https:\/\/aafa.org\/wp-content\/uploads\/2026\/06\/aafa-logo-digital-70.jpg\"){kind=logo}
<\/a> \u00a0![\"\"](\"https:\/\/aafa.org\/wp-content\/uploads\/2026\/06\/COPDF-One-Line_Registered-70.jpg\")
<\/a>\u00a0 ![\"\"](\"https:\/\/aafa.org\/wp-content\/uploads\/2026\/06\/GAAPP_logo_v2-70.jpg\"){kind=logo}
<\/a> ![\"\"](\"https:\/\/aafa.org\/wp-content\/uploads\/2026\/06\/PFF-Logo_Color_Stacked-70.jpg\"){kind=logo}
<\/a><\/div>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|on” admin_label=”Partners Logos – Mobile” module_class=”secondary-intro” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#505050″ text_line_height=”1.5em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” custom_margin=”||3%||false|false” custom_padding=”8px|||||” locked=”off” global_colors_info=”{}”]<\/p>\n
![\"Asthma](\"https:\/\/aafa.org\/wp-content\/uploads\/2026\/06\/aafa-logo-digital-250.jpg\"){kind=logo}
<\/a>\n
<\/a>\n
<\/a>\n
![\"\"](\"https:\/\/aafa.org\/wp-content\/uploads\/2026\/06\/PFF-Logo_Color_Long-300x35.png\"){kind=logo}
<\/a><\/div>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Content Row” module_class=”blog-single” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Page Content” module_class=”secondary-intro” _builder_version=”4.27.6″ _module_preset=”default” text_text_color=”#505050″ text_line_height=”1.5em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” custom_margin=”||3%||false|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
First-ever patient focused drug development meeting for chronic cough will be held in October 2026.<\/em><\/p>\n Washington D.C., June 18, 2026 \u2014 For the first time, a coalition of patient advocacy organizations is uniting to bring the voice of the chronic cough community directly to the U.S. Food and Drug Administration (FDA). The Asthma and Allergy Foundation of America, COPD Foundation, Global Allergy & Airways Patient Platform, and Pulmonary Fibrosis Foundation announce Let\u2019s Talk Cough<\/em><\/a>, a joint effort to document and elevate the lived experience of chronic cough. This initiative aims to capture the full impact of chronic cough across many conditions, current management strategies, unmet medical needs, and treatment outcomes that matter most patients\u2014with the goal of informing the development of new therapies.<\/p>\n On October 28, 2026, Let\u2019s Talk Cough will culminate in a hybrid, externally-led patient-focused drug development (EL-PFDD) meeting, conducted in parallel with the FDA\u2019s PFDD initiative. The meeting will be streamed live, bringing members of the global chronic cough community together to share their experiences and perspectives. A \u201cVoice of the Patient\u201d report will summarize insights gathered during the Let\u2019s Talk Cough meeting and throughout the planning process, creating a resource for researchers, drug makers, regulators, healthcare professionals, and the broader chronic cough community.<\/p>\n Initial discussions about the initiative generated enthusiasm and validated the need for this initiative. “The burden of chronic cough is debilitating. It’s a community that has been systematically dismissed, and Let’s Talk Cough is much needed to elevate the experiences of a community with great unmet needs,\u201d stated Tonya Winders, President of the Global Allergy & Airways Patient Platform.<\/p>\n Chronic cough\u2014defined as a daily or intermittent cough lasting 8 weeks or longer in adults or 4 weeks or longer in children\u2014is commonly associated with chronic lung conditions like asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and pulmonary fibrosis. Let’s Talk Cough is designed to capture that shared experience while honoring the distinct perspectives of each community represented.<\/p>\n “Chronic cough is more than a symptom. It can take a significant toll on quality of life for patients living with a range of lung and respiratory conditions,” said Dr. Amy Hajari Case, Chief Medical Officer of the Pulmonary Fibrosis Foundation. \u201cLet’s Talk Cough gives patients a platform to share the daily burden of living with a persistent cough for which effective treatment options remain inadequate.”<\/p>\n Visit letstalkcough.org<\/a> and complete the sign-up form to receive timely updates about the meeting on October 28, 2026, and other opportunities to participate and spread the word.<\/strong><\/p>\n Let’s Talk Cough is made possible by support from GSK and Trevi Therapeutics. Sponsor support is independent of all programmatic, scientific, and editorial decisions, which remain solely with the host organizations.<\/em><\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”32212,30475″ posts_number=”2″ show_title_and_caption=”off” disabled_on=”on|on|on” _builder_version=”4.27.4″ _module_preset=”default” module_alignment=”center” disabled=”on” global_colors_info=”{}”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Content Row” module_class=”blog-single” _builder_version=”4.18.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Press Contact” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” global_colors_info=”{}”] <\/p>\n Press Contact:<\/strong> The Patient-Focused Drug Development (PFDD) initiative, initiated by the U.S. FDA in 2013, has been instrumental in providing a comprehensive understanding of the lived experience of more than 150 medical conditions to date. As an externally-led PFDD meeting, the October 28, 2026 Let\u2019s Talk Cough meeting provides a unique opportunity for patients with chronic cough to express their experiences, needs, and priorities directly to FDA staff, researchers, and developers of medical therapies. Asthma and Allergy Foundation of America (AAFA)<\/em><\/strong><\/p>\n Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and improving the quality of life for people affected by asthma and allergic diseases through support, advocacy, education, and research. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases. AAFA is the first asthma and allergy patient advocacy group certified to meet the standards of excellence set by the National Health Council. For more information, visit:\u00a0aafa.org<\/a>.<\/p>\n COPD Foundation\u00a0<\/em><\/strong><\/p>\n The COPD Foundation is a nonprofit organization whose mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure. For more information, visit copdfoundation.org.<\/a><\/p>\n Global Allergy & Airways Patient Platform (GAAPP)<\/em><\/strong><\/p>\n Global Allergy & Airways Patient Platform (GAAPP) is a not-for-profit organization whose mission is to globally support and empower patients with allergies, airways and atopic diseases by protecting their rights and insisting on the duties of governments, healthcare professionals and the general public. With more than 200 organizations throughout 80 countries, GAAPP works to create a world where people live & breathe better. For more information, visit www.gaapp.org<\/a>.<\/p>\n
\n
\nAndy Spears
\nPublic Affairs Manager
\nAsthma and Allergy Foundation of America (AAFA)
\nmedia@aafa.org
\n[\/et_pb_text][et_pb_text admin_label=”About AAFA” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ link_line_height=”1.7em” ul_line_height=”1.7em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” background_color=”#F5EDDF” custom_padding=”4%|4%|4%|4%|true|true” box_shadow_style=”preset2″ global_colors_info=”{}”]About PFDD and the Let\u2019s Talk Cough Initiative<\/strong><\/p>\n
\n[\/et_pb_text][et_pb_text admin_label=”About Host Orgs” _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#505050″ link_font=”||||on|||#008c99|” link_text_color=”#008c99″ link_line_height=”1.7em” ul_line_height=”1.7em” header_2_font=”|600|||||||” header_2_text_color=”#008c99″ header_2_font_size=”39px” header_3_font=”|600|||||||” header_3_text_align=”left” header_3_text_color=”#008c99″ header_3_font_size=”28px” background_color=”#F5EDDF” custom_padding=”4%|4%|4%|4%|true|true” box_shadow_style=”preset2″ global_colors_info=”{}”]About the Host Organizations<\/strong><\/p>\n